Will There Be Resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)?

Since the 1950s, there have been concerns about the definition of response in solid tumors and the reliance on quantitative measurements. Gehan and Tefft discuss new guidelines for evaluating response, referred to as RECIST (Response Evaluation Criteria in Solid Tumors), and how they differ from cri...

Full description

Saved in:
Bibliographic Details
Published inJNCI : Journal of the National Cancer Institute Vol. 92; no. 3; pp. 179 - 181
Main Authors Gehan, Edmund A., Tefft, Mariella C.
Format Journal Article
LanguageEnglish
Published United States Oxford University Press 02.02.2000
Oxford Publishing Limited (England)
Subjects
Antineoplastic Agents - therapeutic use
Cancer
Clinical Trials as Topic - methods
Clinical Trials as Topic - standards
Dose-Response Relationship, Drug
Editorials
Guidelines
Humans
Neoplasms - drug therapy
Outcome Assessment (Health Care) - methods
Outcome Assessment (Health Care) - standards
Research Design
Treatment Outcome
Tumors
United States
World Health Organization
United States
Online AccessGet full text

Cover

More Information
Summary:Since the 1950s, there have been concerns about the definition of response in solid tumors and the reliance on quantitative measurements. Gehan and Tefft discuss new guidelines for evaluating response, referred to as RECIST (Response Evaluation Criteria in Solid Tumors), and how they differ from criteria set up by the World Health Organization (WHO).
Bibliography:Correspondence to: E. A. Gehan, Ph.D., Lombardi Cancer Center, Georgetown University Medical Center, 3800 Reservoir Rd., N.W., Washington, DC 20007 (e-mail: gehane@gunet.georgetown.edu).
ark:/67375/HXZ-VJQZK430-J
istex:750B7151375019F4CA88448A0C95F00A0BAD4F53
local:179.sgm
PII:1460-2105
SourceType-Other Sources-1
content type line 63
ObjectType-Editorial-2
ObjectType-Commentary-1
ISSN:0027-8874
1460-2105
DOI:10.1093/jnci/92.3.179